Archives

  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06
  • WIP1 Limits Renal Pyroptosis via p38 MAPK in Septic AKI

    2026-08-03

    WIP1 Phosphatase Regulates Pyroptosis in Sepsis-Related Acute Kidney Injury

    Study Background and Research Question

    Sepsis-associated acute kidney injury (AKI) is a critical complication in intensive care patients, contributing to high morbidity and mortality worldwide. The etiology of septic AKI is complex, involving metabolic dysregulation, microvascular dysfunction, and pronounced renal inflammation. Recent research points to pyroptosis—a form of programmed necrotic cell death mediated by inflammasome activation—as a pivotal driver of tissue injury in this context. However, the endogenous molecular brakes on pyroptosis within kidney tissue during sepsis remain insufficiently characterized. The present study, WIP1-mediated regulation of p38 MAPK signaling attenuates pyroptosis in sepsis-associated acute kidney injury, addresses whether the phosphatase WIP1 (wild-type p53-induced phosphatase 1, PPM1D) modulates pyroptosis in renal tubular cells following septic insult, and delineates the underlying signaling pathways.

    Key Innovation from the Reference Study

    A major contribution of this research is the identification of WIP1 as a negative regulator of p38 MAPK-mediated pyroptosis in the setting of sepsis-induced AKI. The study demonstrates that WIP1 expression increases in renal tubular cells during acute injury and repair phases, and that pharmacological inhibition of WIP1 exacerbates LPS-induced pyroptotic cell death in both mouse and human kidney cell models. Mechanistically, the findings show that WIP1 restrains p38 MAPK phosphorylation, thereby limiting activation of the NLRP3 inflammasome and downstream cleavage of gasdermin-D (GSDMD), a central effector of pyroptosis. This mechanistic link provides new insight into how the kidney may intrinsically counteract inflammatory cell death during septic injury.

    Methods and Experimental Design Insights

    The study employed a multi-layered experimental approach to dissect the role of WIP1 in renal pyroptosis:
    • In vivo sepsis model: Acute kidney injury was induced in mice using lipopolysaccharide (LPS) injection. The WIP1 inhibitor CCT007093 was administered to a subset of animals to assess its effect on injury progression.
    • In vitro cell model: Human kidney 2 (HK2) cells were exposed to LPS, with or without CCT007093 treatment, to evaluate changes in pyroptosis markers and cell viability.
    • Gene and protein expression analysis: Single-cell RNA sequencing (scRNA-seq) tracked Ppm1d (WIP1) mRNA dynamics following unilateral ischemia–reperfusion injury in mice. Western blot and immunohistochemistry were used to quantify WIP1, NLRP3, cleaved-Caspase1, GSDMD-N, and IL-1β protein levels in both tissue and cell samples.
    • Functional assays: Cell viability was measured using CCK-8, while pyroptosis was assessed by detecting the cleaved forms of key effectors.
    • Phosphorylation status: The activation state of p38 MAPK was determined by immunoblotting for phosphorylated p38 in response to LPS and WIP1 inhibition.

    Protocol Parameters

    • LPS induction of AKI: Mice received intraperitoneal LPS at doses sufficient to elicit acute kidney injury, typically 10 mg/kg, with evaluation 24–48 hours post-injection.
    • WIP1 inhibition: CCT007093 was administered at 5 mg/kg in vivo or at 10 μM in vitro, starting concurrently with LPS exposure.
    • scRNA-seq time points: Renal tissue collected at multiple intervals post-ischemia–reperfusion injury, with peak Ppm1d expression observed on day 2 in proximal tubular cells.
    • Pyroptosis marker assessment: Cleaved-Caspase1, GSDMD-N, and IL-1β quantified via western blot and immunostaining in both animal and cell models.
    • MAPK pathway analysis: Phospho-p38 levels measured following LPS and/or WIP1 inhibitor treatment to map signaling dynamics.

    Core Findings and Why They Matter

    The principal findings of the study can be summarized as follows:
    • WIP1 upregulation in injury: Both human patients with acute tubular injury and mouse models of LPS-induced AKI exhibited significant increases in WIP1 expression within the renal tubules.
    • WIP1 suppresses pyroptosis: Inhibition of WIP1 activity (via CCT007093) led to higher levels of NLRP3, cleaved-Caspase1, GSDMD-N, and IL-1β in LPS-injured HK2 cells and mouse kidney tissue, indicating enhanced pyroptosis and inflammatory signaling.
    • p38 MAPK as a critical node: WIP1 inhibition augmented LPS-induced phosphorylation of p38 MAPK, which acted upstream to promote inflammasome activation and pyroptotic cell death.
    These results clarify that WIP1 activity restrains p38 MAPK-driven inflammatory cell death, positioning WIP1 as a potential target for limiting tissue damage in septic AKI. The evidence also strengthens the conceptual link between classic stress-response phosphatases and innate immune cell death pathways in the kidney.

    Comparison with Existing Internal Articles

    Recent internal reviews, such as "WIP1 Phosphatase Attenuates Pyroptosis in Septic AKI via p38 MAPK" and "WIP1 Regulation of p38 MAPK Attenuates Pyroptosis in Sepsis-AKI", have highlighted the emerging role of WIP1 in modulating inflammatory injury through p38 MAPK signaling. The current reference study builds on and extends these findings by providing direct in vivo and in vitro evidence, integrating single-cell transcriptomic analysis with functional assays. These advances move the field beyond correlative observations, elucidating a tangible molecular mechanism. For researchers interested in metabolic regulation and signaling cascades, resources such as "Recombinant Human FGF-19: Benchmarks, Protocols & Applications" and "Reliable Cell Assays with Recombinant Human FGF-19 (E.coli, Tag Free)" provide workflow guidance for cell-based studies exploring related endocrine pathways and receptor activation dynamics. While the current study does not directly address FGF-19, the methodological parallels in cell viability and signaling assays are notable.

    Limitations and Transferability

    Despite its strengths, the study has several limitations. The reliance on LPS as a sepsis model, while standard, may not capture all aspects of human septic AKI. The role of WIP1 was probed primarily via pharmacological inhibition, which could produce off-target effects. Long-term consequences of WIP1 modulation, including effects on repair processes or chronic inflammation, remain unaddressed. Finally, while the link between WIP1, p38 MAPK, and pyroptosis is mechanistically convincing, further studies are needed to determine how these findings translate to clinical outcomes or other forms of kidney injury.

    Research Support Resources

    For laboratories aiming to dissect cell signaling and metabolic regulation in renal or broader endocrine contexts, validated reagents are essential. Recombinant proteins with confirmed biological activity and purity—such as Recombinant Human FGF-19 (E.coli, Tag Free, Lyophilized) (SKU P1050)—can support workflows involving cell viability, receptor binding, or downstream signaling assays. This FGF-19 protein is extensively characterized for FGFR4 binding and biological activity in cell proliferation assays, making it suitable for metabolic regulation research and for studies examining FGF-19 and FGFR4 binding or activity. While not directly investigated in the present WIP1 study, such resources enable rigorous assessment of related signaling pathways and may facilitate the translation of molecular insights into practical research protocols.